GlassScriptPhysician profile
Juan Lacayo
NPI 1245427178
$164,341.97
in general payments reported to CMS, 2019-2025
79 companies · $7,533 in 2025
The $7,533 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $32K · 2021: $43K · 2022: $25K · 2023: $17K · 2024: $15K · 2025: $7,533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $19K · Education: $368 · Travel and Lodging: $342 · Consulting Fee: $150 · Honoraria: $24.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,406.25 |
| Food and Beverage | $19,332.68 |
| Education | $368.43 |
| Travel and Lodging | $342.28 |
| Consulting Fee | $150.00 |
| Honoraria | $24.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $48,564.74 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $32,138.31 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Allergan, INC. | $19,328.74 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $14,072.84 | 2021 | |
| Avanir Pharmaceuticals, INC. | $5,972.40 | 2019-2022 | |
| Sk Life Science, INC. | $4,217.69 | 2020-2025 | Xcopri |
| Supernus Pharmaceuticals, INC. | $3,819.55 | 2019-2025 | Qelbree, Qelbree |
| Biohaven Pharmaceutical Holding Company LTD. | $3,615.99 | 2022 | |
| Jazz Pharmaceuticals INC. | $2,177.59 | 2019-2025 | |
| Eisai INC. | $1,901.66 | 2019-2025 | |
| Ucb, INC. | $1,808.04 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Emd Serono, INC. | $1,482.70 | 2019-2025 | Mavenclad, Mavenclad |
| Amgen INC. | $1,480.43 | 2019-2025 | Uplizna, Aimovig |
| Mdd US Operations, LLC | $1,280.99 | 2019-2025 | Gocovri, Gocovri |
| Sunovion Pharmaceuticals INC. | $1,151.61 | 2019-2022 |
Show all 79 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $1,108.69 | 2019-2025 | Vyepti, Rexulti |
| Neurelis, INC. | $1,094.51 | 2021-2025 | Valtoco |
| Neurocrine Biosciences, INC. | $1,038.32 | 2019-2025 | Ingrezza, Ongentys |
| Upsher-Smith Laboratories LLC | $1,030.85 | 2019-2023 | |
| Lilly USA, LLC | $1,019.72 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Catalyst Pharmaceuticals, INC. | $1,008.29 | 2023-2025 | Fycompa |
| Pfizer INC. | $992.65 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $905.97 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $821.85 | 2019-2025 | Nuplazid, Daybue |
| Argenx US, INC. | $742.59 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Janssen Pharmaceuticals, INC | $674.24 | 2021-2025 | Spravato |
| Sumitomo Pharma America, INC. | $658.26 | 2023-2024 | Aptiom |
| Alexion Pharmaceuticals, INC. | $653.30 | 2019-2025 | Ultomiris, Soliris |
| Otsuka America Pharmaceutical, INC. | $651.15 | 2023-2025 | Rexulti, Nuedexta |
| Greenwich Biosciences, INC. | $631.60 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $628.46 | 2019-2025 | Hyqvia, Trintellix, Gammagard |
| Kyowa Kirin, INC. | $537.96 | 2019-2024 | Nourianz |
| Harmony Biosciences LLC | $500.69 | 2020-2025 | Wakix |
| Csl Behring | $499.93 | 2019-2025 | Hizentra |
| Axsome Therapeutics, INC. | $460.70 | 2023-2025 | Auvelity, Symbravo, Sunosi |
| Amneal Pharmaceuticals LLC | $435.44 | 2019-2025 | Crexont, Rytary |
| Genzyme Corporation | $432.72 | 2019-2025 | |
| Genentech USA, INC. | $419.06 | 2019-2024 | Ocrevus |
| E.R. Squibb & Sons, L.L.C. | $348.38 | 2024-2025 | Zeposia |
| Janssen Biotech, INC. | $302.45 | 2025 | |
| Corium, LLC | $300.76 | 2022-2025 | Azstarys, Adlarity, Adlarity |
| Biogen, INC. | $282.26 | 2019-2025 | Leqembi |
| Ipsen Biopharmaceuticals, INC | $239.40 | 2019-2025 | Dysport |
| Idorsia Pharmaceuticals US INC | $236.97 | 2023-2025 | Quviviq, Quviviq |
| Grifols USA, LLC | $222.81 | 2019-2025 | Gamunex-C |
| Azurity Pharmaceuticals, INC. | $205.51 | 2023-2025 | Horizant, Horizant, Edarbyclor |
| Kedrion Biopharma, INC. | $203.42 | 2024-2025 | Albuked, Rhogam Ultra-Filtered Plus, Kedrab |
| Adamas Pharmaceuticals, INC. | $199.06 | 2019-2021 | |
| Acorda Therapeutics, INC | $180.13 | 2019-2023 | Inbrija |
| Impel Pharmaceuticals INC. | $179.32 | 2022-2023 | Trudhesa |
| Celgene Corporation | $149.44 | 2020-2024 | Zeposia |
| Scilex Pharmaceuticals INC. | $132.49 | 2022-2025 | Ztlido |
| Astrazeneca Pharmaceuticals LP | $107.67 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $104.41 | 2024-2025 | Ponvory |
| Merz Pharmaceuticals, LLC | $88.65 | 2022-2025 | Xeomin |
| Vertical Pharmaceuticals, LLC | $86.26 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $75.75 | 2019-2024 | Jornay Pm |
| Endo Pharmaceuticals INC. | $71.30 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $67.25 | 2022-2023 | Belsomra |
| Mallinckrodt Hospital Products INC. | $66.88 | 2022-2023 | Acthar |
| Octapharma USA, INC. | $66.72 | 2025 | Panzyga |
| Currax Pharmaceuticals LLC | $54.58 | 2020-2021 | |
| Merz North America, INC. | $40.73 | 2019 | |
| Assertio Therapeutics, INC. | $39.80 | 2019-2020 | |
| Aquestive Therapeutics, INC. | $36.92 | 2019-2020 | |
| Almatica Pharma LLC | $32.17 | 2021 | |
| Impel Pharmaceuticals LLC | $29.66 | 2024-2025 | Trudhesa |
| Springworks Therapeutics, INC. | $28.21 | 2025 | Gomekli |
| Mallinckrodt Enterprises LLC | $23.92 | 2019 | |
| Tg Therapeutics, INC. | $22.08 | 2025 | |
| Bausch Health US, LLC | $21.36 | 2020 | |
| Aprecia Pharmaceuticals, LLC | $21.30 | 2020 | |
| Avion Pharmaceuticals | $20.28 | 2022 | |
| Sanofi-Aventis U.S. LLC | $19.04 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.79 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.97 | 2025 | Caplyta |
| Shire North American Group INC | $15.74 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.46 | 2022 | |
| Pernix Therapeutics Holdings, INC. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Lacayo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.